Chipscreen(SH:688321) Sou Hu Cai Jing·2025-11-08 18:05Core Viewpoint - Microchip Biotech (688321) has experienced a slight decline in stock price, closing at 30.41 yuan, down 1.49% from the previous week, with a current market capitalization of 12.401 billion yuan [1] Group 1: Clinical Research Updates - The Phase II clinical trial of Xioroni for pancreatic cancer has enrolled 42 patients, with a 6-month progression-free survival (PFS) rate of nearly 80%, showing better efficacy compared to historical chemotherapy results [3][9] - The sales of Sigleth sodium increased by 125.7% in the first half of 2025, with a year-on-year growth rate of 136.1% in the first three quarters, attributed to successful self-operated and commissioned sales models [4][9] - The Phase III clinical trial of Sidabamine for colorectal cancer has enrolled over 300 patients, leading the domestic competition in similar indications, with expectations to complete most patient enrollments by 2025 [7][9] Group 2: Company Announcements - Microchip Biotech plans to repurchase shares amounting to no less than 10 million yuan and no more than 15 million yuan, with a repurchase price not exceeding 47.46 yuan per share, within a 12-month period [10] - The company has completed GMP compliance checks for the third production line of Sigleth sodium and is advancing GMP certification for the new formulation line, with plans to add a production capacity of 1.2 billion tablets by 2027 [6][9] - The top ten shareholders include Boao Biological Group, holding 30,627,198 shares, representing 7.51% of the total shares [8]